United States · 
Who invested in Immune-Onc Therapeutics?
Immune-Onc Therapeutics's investors include Northern Light Venture Capital and Vivo Capital.
United States · Series B startup
Who invested in Immune-Onc Therapeutics
Funding summaryUpdated 26 Oct 2026
$25Mraised across 1 round since 2023, from 1 source
- Latest round
- Series B, $25MJan 2023
- Investors
- 2
The rounds
- Jan 2023
Founders and team
From the SEC filings it signed: 2 on the team.
- Guo-Liang YuBoard of Directors
- Xiaoling Charlene LiaoExecutive Officer, Directori
On the board, as filediLiqun Luo
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about Immune-Onc Therapeutics
How much has Immune-Onc Therapeutics raised?
Immune-Onc Therapeutics has raised $25M across 1 round since 2023.
When did Immune-Onc Therapeutics last raise?
Immune-Onc Therapeutics's most recent round was a Series B of $25M in Jan 2023.
What was Immune-Onc Therapeutics's biggest round?
Its most recent round, $25M in Jan 2023, is also its largest on record.
Who backed Immune-Onc Therapeutics first?
Immune-Onc Therapeutics's first round on record, in Jan 2023, was backed by Northern Light Venture Capital and Vivo Capital.
What stage is Immune-Onc Therapeutics at?
Immune-Onc Therapeutics's latest named round is a Series B, in Jan 2023.
Where is Immune-Onc Therapeutics based?
Immune-Onc Therapeutics is based in the United States.
Companies like Immune-Onc Therapeutics
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.